Sihuan Pharma Buys Rights to Ebola Drug from China's AMMS

Sihuan Pharmaceutical signed a collaborative development agreement to develop a treatment for Ebola with the Institute of Microbiology and Epidemiology of China's Academy of Military Medical Sciences (AMMS). The Institute discovered jk-0. Although the drug has been approved for military use, no clinical trials of jk-05 have been completed. Sihuan will pay a technology transfer fee of $1.6 million for rights to jk-05. More details.... Stock Symbol: (HK: 460) Share this with colleagues: // //